Equities research analysts expect that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) will post $610,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the highest sales estimate coming in at $610,000.00 and the lowest estimate coming in at $600,000.00. Oramed Pharmaceuticals posted sales of -$930,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 165.6%. The company is expected to announce its next earnings results on Friday, November 24th.

According to Zacks, analysts expect that Oramed Pharmaceuticals will report full year sales of $610,000.00 for the current financial year. For the next year, analysts expect that the business will report sales of $2.40 million per share, with estimates ranging from $2.00 million to $2.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Oramed Pharmaceuticals.

Separately, HC Wainwright set a $25.00 target price on Oramed Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 22nd.

Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) opened at 8.39 on Monday. Oramed Pharmaceuticals has a 12-month low of $5.70 and a 12-month high of $9.17. The company’s market cap is $111.75 million. The stock’s 50 day moving average price is $8.18 and its 200 day moving average price is $7.41.

In other news, Director Xiaopeng Li bought 89,636 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average price of $8.50 per share, for a total transaction of $761,906.00. Following the purchase, the director now directly owns 206,350 shares in the company, valued at approximately $1,753,975. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.50% of the company’s stock.

An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. Virtu KCG Holdings LLC acquired a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 16,077 shares of the biotechnology company’s stock, valued at approximately $125,000. Virtu KCG Holdings LLC owned approximately 0.12% of Oramed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 1.34% of the company’s stock.

WARNING: “Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/04/oramed-pharmaceuticals-inc-ormp-expected-to-post-quarterly-sales-of-610000-00.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.